Crystalline form I of ibrutinib
US9751889B2 · kind B2 · utility
2Cited by
2References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 26, 2014 |
| Grant date | Sep 5, 2017 |
| Priority date | — |
| Expiry date | Nov 26, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Crystalline Form I of ibrutinib, processes for its preparation, pharmaceutical compositions comprising the new Form, and use of Form I of ibrutinib for treating or delaying diseases or disorders related to activity of Bruton's tyrosine kinase (BTK) proteins are disclosed. The novel Form was characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. It can be readily prepared and is suitable for use in the preparation of solid dosage forms.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.